MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma
A single dose of carboplatin was as effective as radiotherapy in preventing relapse of stage I seminoma after orchidectomy, with less time off work and fewer second testicular cancers, so it replaced radiotherapy for men who choose adjuvant treatment.
Overview
Phase 3 non-inferiority trial of 1,477 men with stage I seminoma randomised to adjuvant radiotherapy or one cycle of carboplatin (AUC 7).
Three-year relapse-free rates were 94.8 percent with carboplatin and 95.9 percent with radiotherapy (non-inferior), with fewer contralateral germ cell tumours after carboplatin and less acute toxicity; longer follow-up confirmed equivalence.
- Three-year relapse-free rate 94.8 percent (carboplatin) vs 95.9 percent (radiotherapy); non-inferior.
- Contralateral germ cell tumours 2 vs 10 cases.
Single-dose carboplatin is the adjuvant option for stage I seminoma where surveillance is not chosen; radiotherapy is now rarely used because of second cancer risk.
- Surveillance alone cures the same proportion of men after salvage and is preferred for most today.
Similar pages
not linked directly; found by shared links- CancerTesticular germ cell tumours
Shares Seminoma, Carboplatin.